7Fazio VW,Marchetti F,Church M,et al.Effect of resection margins on the recurrence of Crohn′s disease in the small bowel.A randomized controlled trial[J].Ann Surg,1996,224(4):563.
9Botti F,Carrara A,Antonelli B,et al.The minimal bowel resection in Crohn′s disease:analysis of prognostic factors on the surgical recurrence[J].Ann Ital Chir,74(6):627.
10Resegotti A,Astegiano M,Sostegni R,et al.Stricture plasty in Crohn′s disease.Indications and results[J].Minerva Chir,2000,55(5):313.
7Bernstein CN, Blanchard JF, Kliewer E,et al. Cancer risk in patients with inflammatory bowel disease: a populationbased study. Cancer, 2001,91 (4) :854-862.
8Boeckxstaens GE, Rumessen JJ, Wit L, et al. Abnormal distribution of the interstitial cells of Gajal in an adult patient with pseudo-obstruction and megaduodenum. Am J Gastroenterol, 2002, 97 (7) : 2120.
9Wolters FL, Russel MG, Stockbrugger RW. Systematic review: has disease outcome in Crohnps disease changed during the last four decades?. Aliment Pharmacol Ther, 2004,20 ( 5 ) : 483.
10Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease[ J]. Cochrane Database Syst Rev, 2007, 24( 1 ) :CD000542
2Travis S L. Stange E F, Lemann M. et al. European evidence - based Consensus on the management of ulcerative colitis. Current managernent[J]. J Crohn' s Colitis. 2008. 2 [J]: 24.
3Harnzaoglu H. Cooper 1. Alsahli M, et al. Safety of inflixirnab in Crohn' s disease: a large single - center experience [J]. Inflamm Bowel Dis, 2010,16(12): 2109.
4Rutgeerts P, Van Assche G, Vermeire S. Review article: Inflixirnab therapy for inflammatory bowel disease - - seven years on[J]. Aliment Pharmacal Ther, 2006, 23(4): 451.
5Rutgeerts r. Vermeire S. Van Assche G. Biological therapies for inflammatory bowel disease [J]. Gastroenterology. 2009.136(4): 1182.
6LichensteinGR, FeaganBG. Cohen RD. etal. Serious infections and mortality in association with therapies for Crohn s disease: TREAT registry[J]. Clin Gastroenterol Hepatol, 2006. 4(5). 621.
7Colombel J F. Sandborn W J, Panaccione R. et al. Adalimumab safety in global clinical trials of patients with Crohn' s disease[J]. Inflamm Bowel Dis. 2009. 15(9): 1308.
8Fidder H. Schnitzler F. Ferrante M. et al. Long - term safety of inflixirnab for the treatment of inflammatory bowel disease: a single center cohort study [J]. Gut. 2009. 58 (4): 501.
